LUB017 / Qilu Pharma - LARVOL DELTA

Preclinical Characterization and Development of a Novel BCMA- and CD19- Dual Targeting T Cell Engager, LUB017, Capable of Deep Depletion of B Cells and Autoantibody for the Treatment of Autoimmune Diseases (ACR Convergence 2026) - "LUB017 is a Novel BCMA/CD19 dual‑targeting TCE that combines potent B‑cell depletion with effective autoantibody clearance and deep lymphoid remodeling, coupled with low cytokine release. These preclinical data strongly support its clinical development for the treatment of SLE and other antibody‑driven autoimmune diseases."

IO biomarker • Preclinical • Immunology • Inflammation • Inflammatory Arthritis • CD19 • TNFA